Madison
Madison
Madison, Mississippi, United States29 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Study of Intravitreal 4D-150 in Adults With Diabetic Macular Edema (DME) (4D-150-C005) | eye disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07867080 | |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) | Diabetes Complications, cardiovascular disorder, diabetes mellitus, diabetic peripheral angiopathy, diabetic retinopathy, endocrine system disorder, eye disorder, macular degeneration, macular retinal edema, retinal degeneration, retinal disorder, vascular disorder | Recruiting | Phase 3 | 2026-10-09 | NCT07705555 | |
| A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 3 | 2026-10-07 | NCT05726227 | |
| Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, X-linked disease, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemophilia B, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Recruiting | Phase 3 | 2026-10-07 | NCT05568719 | |
| A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) | Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Recruiting | Phase 2 / Phase 3 | 2026-10-02 | NCT07440225 | |
| A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-30 | NCT06571045 | |
| MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study | bone disorder, lumbar spinal stenosis, musculoskeletal system disorder, spinal stenosis, vertebral column disorder | Recruiting | Not stated | 2026-09-30 | NCT03072927 | |
| A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | Neovascular Age-related Macular Degeneration; nAMD | Recruiting | Phase 3 | 2026-09-29 | NCT07614776 | |
| A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Active, not recruiting | Not stated | 2026-09-29 | NCT05911763 | |
| A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Not stated | 2026-09-22 | NCT06779773 | |
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy | Geographic Atrophy, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Recruiting | Phase 3 | 2026-09-18 | NCT06541704 | |
| A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO | Embolism and Thrombosis, Venous Thrombosis, cardiovascular disorder, eye disorder, retinal disorder, retinal vein occlusion, thrombotic disease, vascular disorder | Recruiting | Phase 2 | 2026-09-04 | NCT07205887 | |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME) | diabetic macular edema | Active, not recruiting | Phase 1 | 2026-09-02 | NCT06847854 | |
| Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) | Neovascular Age-related Macular Degeneration (nAMD) | Active, not recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT05769153 | |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | Abnormalities, Multiple, Arrhythmias, Cardiac, COVID-19, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Coronaviridae Infections, Down syndrome, Dyssomnias, Edema, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Hemic and Lymphatic Diseases, Hemorrhage, Infant, Newborn, Diseases, Infant, Premature, Diseases, Infections, Inflammation, Kawasaki disease, Lung Injury, Menorrhagia, Menstruation Disturbances, Neurobehavioral Manifestations, Neurologic Manifestations, Nidovirales infectious disease, Nutritional and Metabolic Diseases, Orthocoronavirinae infectious disease, Pain, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, Signs and Symptoms, Skin and Connective Tissue Diseases, Sleep Disorders, Intrinsic, Suppuration, Urogenital Diseases, Uterine Hemorrhage, Ventilator-Induced Lung Injury, Water-Electrolyte Imbalance, adrenal gland disorder, adrenal gland hyperfunction, adrenocortical insufficiency, attention deficit hyperactivity disorder, inattentive type, blood coagulation disease, bronchopulmonary dysplasia, cardiovascular disorder, cellulitis, chromosomal disorder, coagulation protein disease, connective tissue disorder, endocrine system disorder, female reproductive system disorder, heart disorder, heart failure, hematologic disorder, hemophilia A, hemorrhagic disease, hereditary disease, hyperaldosteronism, hyperphosphatemia, hypertensive disorder, inherited blood coagulation disorder, insomnia, intellectual disability, lung disorder, lymphatic system disorder, metabolic disease, nervous system disorder, neurodevelopmental disorder, oppositional defiant disorder, pediatric multisystem inflammatory disease, COVID-19 related, phosphorus metabolism disease, pneumonia, potassium deficiency disease, primary aldosteronism, psychiatric disorder, pulmonary arterial hypertension, pulmonary hypertension, respiratory system disorder, respiratory tract infectious disorder, skin disorder, skin disorder caused by infection, skin infection, skin vascular disease, sleep-wake disorder, uterine disorder, vascular disorder, vascular hemostatic disease, vasculitis, viral infectious disease, viral pneumonia | Recruiting | Not stated | 2026-08-21 | NCT04278404 | |
| A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME | Diabetic Macular Edema (DME) | Active, not recruiting | Phase 2 / Phase 3 | 2026-08-20 | NCT06957080 | |
| A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Recruiting | Phase 2 / Phase 3 | 2026-08-18 | NCT05431088 | |
| Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | Eye Diseases, Hereditary, Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-08-03 | NCT05407636 | |
| A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio | Geographic Atrophy Secondary to Age-related Macular Degeneration | Recruiting | Phase 2 | 2026-06-24 | NCT07215390 | |
| A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, anemia, familial hemolytic anemia, hematologic disorder, hemolytic anemia, hereditary disease, inherited hemoglobinopathy, sickle cell disease | Active, not recruiting | Phase 2 / Phase 3 | 2026-06-23 | NCT05031780 | |
| STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 4 | 2026-06-02 | NCT06571383 | |
| 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration | eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-06-01 | NCT06864988 | |
| A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, X-linked disease, blood coagulation disease, coagulation protein disease, hematologic disorder, hemophilia A, hemophilia B, hemorrhagic disease, hereditary disease, inherited blood coagulation disorder | Active, not recruiting | Phase 3 | 2026-06-01 | NCT03861273 | |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration | Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Sensation Disorders, Signs and Symptoms, blindness (disorder), eye disorder, nervous system disorder, vision disorder, wet macular degeneration | Active, not recruiting | Phase 3 | 2026-05-22 | NCT06856577 | |
| A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy | Geographic Atrophy, age-related macular degeneration, eye disorder, macular degeneration, retinal degeneration, retinal disorder | Active, not recruiting | Phase 2 | 2026-05-14 | NCT06722157 |